| Literature DB >> 30555740 |
Qi Huang1, Qi Tan1, Kaimin Mao1, Guanghai Yang2, Guangzhou Ma1, Ping Luo3, Sufei Wang1, Peiyuan Mei2, Feng Wu1, Juanjuan Xu1, Mengfei Guo1, Zhilei Lv1, Jinshuo Fan1, Shuai Zhang1, Xuan Wang1, Yang Jin1.
Abstract
Adrenergic receptors (ARs), especially β-ARs, are constitutively expressed in most mammalian cells and are associated with various malignancies including lung cancer. Epidemiologic studies have reported that activation of β-AR signalling promotes the development and progression of lung cancer and that pharmacological interference by β-AR blockers could partially reverse lung cancer progression. In this review, we mainly focus on the role of β-ARs in lung cancer and then reveal the possible application of AR blockers in anti-tumour therapy for lung cancer.Entities:
Keywords: ADRB2; β-adrenergic receptor; β-adrenergic receptors
Year: 2018 PMID: 30555740 PMCID: PMC6291649
Source DB: PubMed Journal: Am J Cancer Res ISSN: 2156-6976 Impact factor: 6.166